



UPDATED MANAGEMENT OF HEPATITIS C VIRUS DISEASES IN EGYPT

Essay

***Submitted for Partial Fulfillment of Master
Degree
in Internal Medicine***

Submitted By

Ramy Abd-El-Rahman Hussin Hassan

M.B., B.Ch.

Supervised By

Prof. Dr. Mohsen Mostafa Maher

Professor of Internal Medicine

Faculty of Medicine - Ain Shams University

Dr. Moataz Mohamed Sayed

Assistant Professor of Internal Medicine

Faculty of Medicine

Ain Shams University

Dr. Wael Ahmed Yousry

Assistant Professor of Internal Medicine

Faculty of Medicine

Ain Shams University

**Faculty of Medicine
Ain Shams University**

List of Contents

Title	Page No.
List of Abbreviations	ii
List of Tables	v
List of Figures	vi
Introduction and aim of the work	١
Chapter (١): Molecular biology of HCV	٥
Chapter (٢): The origin and epidemiology of HCV type ٤ in different geographic regions.....	١٨
Chapter (٣): Clinical characteristics & the natural course of HCV	٢١
Chapter (٤): Diagnosis of HCV Disease	٢٥
Chapter (٥): Management of HCV	٣٠
Chapter (٦): Medical treatment.....	٣٧
Chapter (٧): Herbs & HCV	١٠٣
Chapter (٨): Vaccinations of HCV	١١٢
References	١٢٦
Arabic summary.....	--

List of Abbreviations

AICAR	: α -amino- β -D-ribofuranosyl-imidazole- ϵ -carboxamide
ALT	: Alanine aminotransferase
AKR	: Aldoketoreductase
ART	: Antiretroviral therapy
AST	: Aspartate aminotransferase
AUC	: Area under the curve
BMI	: Body mass index
BOC	: Bocepriver
C_{max}	: Maximum concentration
C_{min}	: Minimum concentration
CD⁺	: Cluster of Differentiation ⁺
CID	: Chimpanzee infectious doses
CLDN	: Claudin-
CMV	: Cytomegalovirus
CREs	: Cis-acting replication elements
CTLs	: Cytotoxic T-lymphocytes
D⁺	: Domain ⁺
DCs	: Dendritic cells
DGL	: Deglycyrrhizinated licorice
E⁺	: Envelop protein ⁺
E⁺	: Envelop protein ⁺
EGFR	: Epidermal growth factor receptor
EIA	: Enzyme immune assay
EMCV	: Encephalomyocarditis virus
ESR	: Estrogen receptor
EVR	: Early virologic response

List of Abbreviations (Cont...)

FUSE	Far-upstream element
FXR	Farnesoid X receptor
GGT	Gamma glutamyltransferase
GWAS	Genome-wide association study
HCV	Hepatitis C virus
HCVCC	Hepatitis C virus cell culture
HDL	High density lipoprotein
HOMA	Homeostasis model assessment
HSV	Herpes simplex virus
Huh[✓]	Human "hemochromatotic" cell line
Hvap	Human vesicle-associated membrane protein
IL-[✓]^	Interleukin [✓] ^
IRES	Internal ribosomal entry site
IRF	Interferon-regulatory factor
IPS	Interferon promoter stimulator
ISGF	Interferon-stimulated gene factor
kc^z	Ketoconazole
LDL	Low density lipoprotein
LDS	Lipid droplets
MHC	Major histocompatibility complex
miR	microRNAs
MTP	Microsomal triglyceride protein
NK	Natural killer
NTRs	Non translated RNA segments
OCLN	Occludin
ORF	Open reading frame

List of Abbreviations (Cont...)

PCR	Polymerase chain reaction
PEG -INF	Pegylated interferon
PPAR	Peroxisome proliferator-activated receptor
RBV	Ribavirin
RGT	Response guided therapy
RIBA	Recombinant immunoblot assay
RIG	Retinoic acid inducible gene
ROS	Reactive oxygen species
RVR	Rapid virological response
SGOT	Serum glutamic-oxaloacetic transaminase
SGPT	Serum glutamic pyruvic transaminase
SNMC	Neo-Minophagen C
SNP	Single nucleotide polymorphism
SOC	Standard of care
SOCS	Suppressor of cytokine signaling
SVR	Sustained virological response
TLRs	Toll-like receptors
TMA	Transcription-mediated nucleic acid amplification assay.
TNF	Tumor necrosis factor
TRIF	Toll/IL-1R domain-containing adapter-inducing IFN
TVR	Telaprevir
UTR	Untranslated region
VKH	Vogt-Koyanagi-Harada
VLDL	Very low density lipoprotein

List of Tables

Table No.	Title	Page No.
Table (١):	Adverse reactions in combination with Bocepriver with peginterferon alfa-٧b and Ribavirin reported during clinical trials.	٧٣
Table (٢):	Drug-drug interaction of both bocepriver & telapriver.	٧٦
Table (٣):	Prophylactic HCV Vaccine Studies in Chimpanzees.....	١١٥
Table (٤):	HCV Immunotherapeutic Vaccine Studies.....	١٢٤

List of Figures

Fig. No.	Title	Page No.
Fig. (١):	Global distribution of HCV.	٥
Fig. (٢):	Structure of HCV	٧
Fig. (٣):	Schematic representation of HCV genome.....	٨
Fig. (٤):	Mechanism of action of Interferon	١٧
Fig. (٥):	Mechanism of action of interferon	٤٠
Fig. (٦):	Sustained virological response (SVR) rates in treatment naïve patients with genotype ١ chronic HCV infection	٦٧
Fig. (٧):	Sustained virological response (SVR) rates, overall and according to race, in treatment-naïve patients with genotype ١ chronic HCV infection.....	٧٢

INTRODUCTION

Hepatitis is the Latin word for liver inflammation. Type C hepatitis is caused by hepatitis C virus, which is a small (50-60 nm), enveloped, single-stranded, positive sense RNA virus (*Ryan and Ray, 2004*).

HCV virus is divided into the following genotypes: (1, 2.... & 6). They are further divided into sub-types some of which are: (A, B, C ... ect) (*Westin et al., 2006*).

HCV is the most common leading cause of chronic liver disease, cirrhosis & hepatocellular carcinoma, as well as the most common indication for liver transplantation in many countries (*Romero-Gomez et al., 2009*).

The worldwide reservoir of chronically infected persons is estimated at about 150 million, or 3% of the global population (*Wasley and Alter. 2000*).

Egypt has the highest HCV seroprevalence in the world estimated at 10-15% of the country's population. Most cases of HCV are due to genotype 1 viruses, which are uncommon in the west and understudied (*Mohamed. 2004*).

The major known risk factors associated with HCV infection in Egypt are: past history of anti-schistosomal injections, circumcision, or other procedures performed by non-medical personnel, transfusion of blood, birth to an infected

mother, and intranasal cocaine use. Symptoms of acute hepatitis C infection include: loss of appetite, fatigue, abdominal pain, jaundice, itching, & flu-like symptoms & about 60-70% of patients are asymptomatic during the acute phase. Hepatitis C genotypes 1A&1A have the highest cure rates at 81% and 54% respectively. While in chronic hepatitis C infection, it is often asymptomatic and is mostly discovered accidentally, and so blood test before marriage or any sexual contacts is essential (*Caruntu and Benea, 2007*).

Interferon, which is an immune modulator, was the first medication approved for the treatment of hepatitis C virus; in 1996 came the next improvement with the addition of Ribavirin. Early treatment of acute hepatitis C with Interferon monotherapy (pegylated interferon alfa-1b) is highly effective, producing sustained virological response rates of 80% or higher (*Deterding et al., 2009*).

Recently, combination with Ribavirin, a greater number of patients are able to clear the virus (*Herrera and Roveda, 1999*).

The PROVE1 study demonstrated that addition of Telaprevir to the current treatment regimen improved virologic response to HCV (*McHutchison et al., 2009*).

Also the use of Albumin interferon gives good results when used every 2 weeks in combination with Ribavirin. (*Davis et al., 2007*).

New research finds the anti-diabetic drug Metformin, and **AICAR**, can prevent the hepatitis C virus from replicating in the body (*Richard Ashby*, ۲۰۱۰).

Herbal use such as milk thistle& tea made with licorice may help protect the liver from the dramatic effects of the virus. (*Gazák et al.*, ۲۰۰۷).

Liver transplantation is the last chance for someone whose hepatitis C has progressed to end stage liver disease (*Schuppan and Afdhal*, ۲۰۰۸).

HCV vaccine:

In spite that there are vaccinations for hepatitis A&B viruses, the hepatitis C virus still has no vaccinations till now &researches are still going on to find one (*Jacobson et al.*, ۲۰۱۰).

AIM OF THE WORK

The aim of the work is to review & discuss the new trends & drugs available in managing hepatitis C virus diseases.

MOLECULAR BIOLOGY OF HEPATITIS C VIRUS

In the 1980's, investigators from the Centers for Disease Control (headed up by Daniel W. Bradley) and Chiron (Michael Houghton) identified HCV, which is a small (50 - 70 nm), spherical, enveloped, hepatotropic RNA virus prototype, member of the Flaviviridae family, the Hepacivirus genus (from the Greek hepar, hepato, liver) is further classified into genotypes that differ by about 30% in their nucleotide sequence. These genotypes (1, 2, 3..., 6) show differences with regard to their worldwide distributions, transmission & disease; they have been further classified into sub-types (a, b, c, d, etc). (Fig. 1) (*Thein and Dore, 2009*)




Fig. (1): Global distribution of HCV.

HCV type 1 virus is the dominating virus found throughout The Middle East and parts of Africa, often in Egypt. Molecular studies of HCV began with the successful cloning of its genome in 1989 (*Kuiken et al., 1989*).

Even though HCV is detected and targeted by host immune mechanisms, it establishes and maintains a life-long persistent infection. HCV has evolved multiple strategies to survive and persist in hostile cellular environments, and the viral population is known to rapidly change during the course of a natural infection thereby escaping immune surveillance (*Von Hahn et al., 1996*).

Although precise mechanisms regulating HCV entry into hepatic cells via receptors remain unknown, HCV also has the capability of direct cell-to-cell transmission. The extremely complex and incompletely understood nature of the HCV lifecycle has complicated the discovery of new therapies (*Diviney et al., 1998*).

A break through in the field came with the development of a complete in vitro cell culture system for HCV (JFH1) in 2000 (*Wakita et al., 2000*).

Present inside the outer envelope, there is a (30-35 nm) inner core which encapsulates the single-strand viral RNA (positive-sense), which is approximately 9.6 kb (Fig. 2).




Fig. (1): HCV particle structure: core protein interacts with viral genomic RNA to form the nucleocapsid. Two membrane-associated envelope glycoproteins, E1 and E2 are embedded in a lipid envelope which is derived from the host (*Cheng et al., 2009*).

The HCV genome does not enter the cell nucleus. HCV-RNA replication occurs in the cytoplasm of hepatocytes. The genomic organization of HCV is shown schematically in **Fig. 2**.

The viral-RNA genome harbors a single ORF which is flanked by 5' and 3' NTRs. The CREs are located in both the 5' and 3' NTRs and in the NS5B coding sequence (*Diviney et al., 2004*).




Fig. (3): The genome consists of a single ORF which is translated to produce a single protein product. At the 5' and 3' ends of the RNA are the UTR, which are important to translation and replication of the viral RNA. The 5' UTR has IRES that starts the translation of a very long protein of about 3000 amino acids. Structural proteins made by the hepatitis C virus include Core protein, E1 and E2; nonstructural proteins include NS1, NS2, NS3, NS4A, NS4B, NS5A, and NS5B. (Dubuisson J, 2001)

This CRE is called as SL⁹²⁶⁶ (or ^oBSL^{3,4}) and it was found that its disruption blocks RNA replication (Friebe *et al.*, 2005).

The 5'- and the 3'-NTRs of the genome are highly conserved and contain control elements for translation of the viral polyprotein and replication. The 5' UTR contains IRES which is required for cap-independent translation of viral RNA, which is carried out by host cell ribosome (Shimoike *et al.*, 2009).

A recent study identified a cellular factor called FUSEbinding protein FBP which binds to 3'NTR by interacting with the poly (U) tract (Zhang *et al.*, 2004).